SG11202108026UA - Neurotensinergic agonists and methods of using same preventing or treating pain - Google Patents

Neurotensinergic agonists and methods of using same preventing or treating pain

Info

Publication number
SG11202108026UA
SG11202108026UA SG11202108026UA SG11202108026UA SG11202108026UA SG 11202108026U A SG11202108026U A SG 11202108026UA SG 11202108026U A SG11202108026U A SG 11202108026UA SG 11202108026U A SG11202108026U A SG 11202108026UA SG 11202108026U A SG11202108026U A SG 11202108026UA
Authority
SG
Singapore
Prior art keywords
neurotensinergic
agonists
methods
treating pain
same preventing
Prior art date
Application number
SG11202108026UA
Inventor
Éric Marsault
Michael Desgagne
Marc Sousbie
Philippe Sarret
Magali Chartier
Jean-Michel Longpre
Original Assignee
Socpra Sciences Sante Et Humaines S E C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Sante Et Humaines S E C filed Critical Socpra Sciences Sante Et Humaines S E C
Publication of SG11202108026UA publication Critical patent/SG11202108026UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11202108026UA 2019-02-08 2020-02-10 Neurotensinergic agonists and methods of using same preventing or treating pain SG11202108026UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962803041P 2019-02-08 2019-02-08
PCT/CA2020/050176 WO2020160685A1 (en) 2019-02-08 2020-02-10 Neurotensinergic agonists and methods of using same preventing or treating pain

Publications (1)

Publication Number Publication Date
SG11202108026UA true SG11202108026UA (en) 2021-08-30

Family

ID=71947132

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108026UA SG11202108026UA (en) 2019-02-08 2020-02-10 Neurotensinergic agonists and methods of using same preventing or treating pain

Country Status (10)

Country Link
US (1) US20220168383A1 (en)
EP (1) EP3921331A4 (en)
JP (1) JP2022523920A (en)
KR (1) KR20210126022A (en)
CN (1) CN113677692A (en)
AU (1) AU2020218577A1 (en)
BR (1) BR112021015337A2 (en)
CA (1) CA3127387A1 (en)
SG (1) SG11202108026UA (en)
WO (1) WO2020160685A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491922A1 (en) * 1980-10-14 1982-04-16 Roussel Uclaf NOVEL HEXAPEPTIDES, PROCESS FOR THEIR PREPARATION AND APPLICATION AS MEDICAMENTS
PL1648922T3 (en) * 2003-07-31 2011-05-31 Tranzyme Pharma Inc Spatially-defined macrocyclic compounds useful for drug discovery
AU2008241532A1 (en) * 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US11591366B2 (en) * 2017-06-16 2023-02-28 Socpra Sciences Santé Et Humaines S.E.C. Macrocyclic compounds and methods of preventing or treating pain

Also Published As

Publication number Publication date
BR112021015337A2 (en) 2021-10-05
JP2022523920A (en) 2022-04-27
US20220168383A1 (en) 2022-06-02
EP3921331A4 (en) 2022-11-23
CA3127387A1 (en) 2020-08-13
CN113677692A (en) 2021-11-19
AU2020218577A1 (en) 2021-08-19
EP3921331A1 (en) 2021-12-15
KR20210126022A (en) 2021-10-19
WO2020160685A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
IL273824A (en) Methods of using ehmt2 inhibitors in treating or preventing blood disorders
IL272137A (en) Interleukin-21 muteins and methods of treatment
IL279748A (en) Composition and method for treating pain
IL283592A (en) Inhibitors of apol1 and methods of using same
IL279475A (en) Ectonucleotidase inhibitors and methods of use thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
EP3706737A4 (en) Ash1l inhibitors and methods of treatment therewith
IL287973A (en) Acss2 inhibitors and methods of use thereof
EP3773266A4 (en) Improved devices for tissue treatment and methods of use thereof
EP3691748A4 (en) Acetaminophen-pregabalin combinations and methods of treating pain
IL286149A (en) Caspase inhibitors and methods of use thereof
EP4138852A4 (en) Compositions and methods for the treatment of pain
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
EP4017493A4 (en) Methods of treatment using bcn057 and bcn512
SG11202108026UA (en) Neurotensinergic agonists and methods of using same preventing or treating pain
IL268111A (en) Methods of treating pain
EP3833353A4 (en) Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
EP3758692A4 (en) Compositions and methods for treating pain
GB201810923D0 (en) Compositions and method of treatment
EP3784261A4 (en) Compositions and methods for prophylaxis or treatment of pain
GB2574944B (en) Methods and compositions for the treatment of pain and/or inflammation
IL288524A (en) Methods of treating and/or preventing psoriasis
GB201901219D0 (en) Compositions and methods of treatment
GB201810925D0 (en) Compositions and methods of treatment